Introduction. Primary varicella usually occurs in childhood and is generally self-limiting. In adults and immunocompromised individuals, it can have a more serious course. Obesity is one of the risk factors for a severe COVID-19 infection that can lead to immunosuppression among other systemic complications. This case report aims to present a rare co-infection of varicella-zoster virus and SARS-CoV-2 in an adult, as well as to evaluate the impact of this co-infection on the progression and severity of both diseases in order to highlight the significance of antiviral therapy in treating both infections. Case report. We report a case of a 34-year-old obese woman with varicella-zoster virus and SARS-CoV-2 co-infection who was successfully treated with oral acyclovir and nirmatrelvir-ritonavir without developing significant complications. Conclusion. Currently, there is not enough evidence to claim that co-infection with varicella-zoster virus and SARS-CoV-2 increases the chances of a more severe form of either of these infections. With effective antiviral therapy, it is possible to significantly reduce the chances of developing more severe forms of both infections, which physicians need to be aware of in case they come across it and respond promptly.
Kim SR, Khan F, Tyring SK. Varicella zoster: an update on current treatment options and future perspectives. Expert Opinion on Pharmacotherapy. 2014;15(1):61–71.
3.
Andrei G, Snoeck R. Advances and Perspectives in the Management of Varicella-Zoster Virus Infections. Molecules. 26(4):1132.
4.
University of Liverpool COVID-19 Drug interaction database.
5.
Food US, Administration D. Fact sheet for healthcare providers: emergency authorization for Paxlovid. 2022;
6.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine. 2022;386(15):1397–408.
7.
Lopez‐Trujillo E, Rodriguez Mercader S, Güerri‐Fernández R, Arrieta Aldea I, Pujol RM, Martin‐Ezquerra G. Varicella complicated with pneumonia in a patient infected by COVID‐19: the need to rule out other viral coinfections in SARS‐CoV‐2 patients with vesicular eruptions. International Journal of Dermatology. 2021;60(7):886–8.
8.
Loh J, Tham SM, Tambyah PA, Yan G, Lee CK, Chai LYA. Range of Varicella Zoster Co-Infections with COVID-19, Singapore. Infection & Chemotherapy. 2021;53(2):391.
9.
Bruno J, Ragozzino S, Quitt J, Siegemund M, Labhardt N. Severe acute respiratory syndrome coronavirus 2, primary varicella zoster virus coinfection, and a polymicrobial ventilator-associated tracheobronchitis in an adult immunocompetent male: a case report. Journal of Medical Case Reports. 2022;16(1).
10.
Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, et al. Individuals with obesity and COVID‐19: A global perspective on the epidemiology and biological relationships. Obesity Reviews. 2020;21(11).
11.
Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nature Reviews Immunology. 2020;20(7):397–8.
12.
Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clinical Infectious Diseases. 2020;71(15):762–8.
13.
WHO Director-General’s opening remarks at the media briefing on. 2020;
14.
Tunbridge AJ, Breuer J, Jeffery KJM. Chickenpox in adults – Clinical management. Journal of Infection. 2008;57(2):95–102.
15.
Singh H, Kaur H, Singh K, Sen CK. Cutaneous Manifestations of COVID-19: A Systematic Review. Advances in Wound Care. 2021;10(2):51–80.
16.
Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & Molecular Immunology. 2020;17(5):533–5.
17.
Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. The Journal of Infectious Diseases. 2020;221(11):1762–9.
18.
Kennedy PGE, Gershon AA. Clinical Features of Varicella-Zoster Virus Infection. Viruses. 10(11):609.
19.
Freer G, Pistello M. Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies. New Microbiol. 2018;41:95–105.
20.
Huttunen R, Syrjänen J. Obesity and the risk and outcome of infection. International Journal of Obesity. 2013;37(3):333–40.
21.
Alwarawrah Y, Kiernan K, MacIver NJ. Changes in Nutritional Status Impact Immune Cell Metabolism and Function. Frontiers in Immunology. 9.
22.
Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its Impact on Patients with COVID-19. SN Comprehensive Clinical Medicine. 2020;2(8):1069–76.
23.
Rahman S, Montero MTV, Rowe K, Kirton R, Kunik F. Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. Expert Review of Clinical Pharmacology. 2021;14(5):601–21.
24.
Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koyfman A, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. The American Journal of Emergency Medicine. 2022;54:46–57.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
,
